Miraq Improve surgical outcomes, demonstrate quality, and increase cost-efficiency. Combining the spatial information from epicardial ultrasound imaging and quantitative data from TTFM enables the surgeon to perform a prompt and accurate assessment, and revise the graft when necessary.
One million beating hearts later, MEDISTIM have set the standard in the field.
Today, Medistim’s proprietary products are regarded to be standard-of-care in most European countries and Japan, while market adoption is growing in the USA, Asia and the Middle East. In addition, Medistim in Norway represents about 100 different medical technology companies, as a distributor of their products in this country.
The company is a market leader within intra-operative transit time flow measurement (TTFM) and ultrasound imaging, providing the MiraQ™ system to the global market. These systems enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. They provide clinically relevant information that empowers surgeons to make better-informed decisions in the operating room.
MEDISTIM’s devices are developed by working closely together with surgeons, who in turn have produced a growing amount of clinical data and studies that point to their efficacy and cost-effectiveness. Medistim is committed to continuing to serve the cardiac and vascular surgeons by investing in new product development.
Medistim has wholly owned subsidiaries with marketing and sales organizations in the USA, Germany, the United Kingdom, Spain, Denmark and Norway, in addition to a global distributor network representing the company in more than 50 countries in Asia, Europe, America and Africa. Sales revenues reached MNOK 363.7 MNOK (325.9 MNOK) in 2019, a growth of 11.6%. Medistim ASA is listed on the Oslo Stock Exchange and has its global head office in Oslo, Norway.